Ayala Pharmaceuticals Inc Revenue Growth Rates (ADXS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ayala Pharmaceuticals Inc   (ADXS)
 

ADXS's Revenue Growth by Quarter and Year

Ayala Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ADXS Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December 0.00
3rd Quarter September 0.00
2nd Quarter June 0.01
1st Quarter March 0.00
FY 0.01

ADXSs Annual Revenue
Ayala Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 0.01 millions
Ayala Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 0.25 millions
Ayala Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 3.24 millions
Ayala Pharmaceuticals Inc 's Revenue in the fiscal year 2020 $ 0.25 millions
Ayala Pharmaceuticals Inc 's Revenue in the fiscal year 2019 $ 20.88 millions




ADXS Revenue fourth quarter 2023 Y/Y Growth Comment
Ayala Pharmaceuticals Inc in the fourth quarter 2023 recorded of $ 0.00 millions.

According to the results reported in the fourth quarter 2023, Ayala Pharmaceuticals Inc achieved the best Revenue growth in Major Pharmaceutical Preparations industry. While Ayala Pharmaceuticals Inc ' s Revenue meltdown of -100% ranks overall at the positon no. in the fourth quarter 2023.


ADXS Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - -81.88 % 452 % -78.99 %
FY   -97.22 % -77.91 % -12.83 % -

Financial Statements
Ayala Pharmaceuticals Inc 's fourth quarter 2023 Revenue $ 0.00 millions ADXS's Income Statement
Ayala Pharmaceuticals Inc 's fourth quarter 2022 Revenue $ 0.11 millions Quarterly ADXS's Income Statement


ADXS Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - -81.88 % -
1st Quarter March - - -14.81 % -
FY (Year on Year)   -97.22 % -77.91 % -12.83 % -


Back to ADXS Growth rate Comparisons >> Back to ADXS Growth rate Comparisons >>


Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Ayala Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ADXS's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ADXS's IV. Quarter Q/Q Revenue Comment


Ayala Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Dec 31 2023 period, Ayala Pharmaceuticals Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Ayala Pharmaceuticals Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Dec 31 2023 period, Ayala Pharmaceuticals Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Ayala Pharmaceuticals Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ADXS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue meltdown for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Healthcare Services Group Inc -0.04%$ -0.042 millions
Integra Lifesciences Holdings Corp-0.25%$ -0.247 millions
Nrc Health-0.37%$ -0.375 millions
Skinhealth Systems Inc -0.63%$ -0.633 millions
3m Company-0.82%$ -0.817 millions
Enhabit Inc -0.95%$ -0.950 millions
Viatris Inc -1.00%$ -0.998 millions
Aspira Women s Health inc -1.07%$ -1.068 millions
Supernus Pharmaceuticals inc -1.80%$ -1.801 millions
Opko Health Inc -1.85%$ -1.853 millions
Quest Diagnostics Inc-1.93%$ -1.929 millions
Koru Medical Systems Inc -2.16%$ -2.161 millions
Envista Holdings Corporation-2.30%$ -2.300 millions
Ideaya Biosciences Inc -2.46%$ -2.461 millions
Zynex inc -3.11%$ -3.114 millions
Shl Telemedicine Ltd-3.26%$ -3.259 millions
Pediatrix Medical Group Inc -3.39%$ -3.386 millions
Baxter International Inc -3.55%$ -3.550 millions
Caribou Biosciences Inc -3.63%$ -3.629 millions
Gilead Sciences Inc -3.72%$ -3.722 millions
Lifevantage Corp-3.92%$ -3.921 millions
Avantor Inc -4.02%$ -4.022 millions
Sensus Healthcare Inc -4.11%$ -4.106 millions
Outset Medical Inc -4.17%$ -4.168 millions
Journey Medical Corp-4.44%$ -4.441 millions
Escalon Medical Corp -4.53%$ -4.533 millions
Waters Corporation-4.55%$ -4.547 millions
Inovio Pharmaceuticals Inc -4.55%$ -4.553 millions
Biolase Inc -4.68%$ -4.683 millions
American Shared Hospital Services-4.73%$ -4.725 millions


About Ayala Pharmaceuticals Inc Revenue Growth Rates (ADXS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ayala Pharmaceuticals Inc (CIK 1100397).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-24-014822
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ayala Pharmaceuticals Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.